There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
HOME > COLUMN
COLUMN
-
Blue Ocean Recruiting
December 20, 2013
-
Recruitment: Save Yourself from the Insanity of Diminished Returns
November 22, 2013
-
Current Topics in the Pharmaceutical Industry: Emerging Therapeutics with New Modes of Action: 2
November 8, 2013
-
Current Topics in the Pharmaceutical Industry: Emerging Therapeutics with New Modes of Action: 1
November 7, 2013
-
A World of Opportunity for the Brave
November 1, 2013
-
Does HR Have an Image Problem?
September 20, 2013
-
Learn How to Give a Great Presentation and You May Break the “Gaijin Ceiling” to the Board Room at Headquarters
August 21, 2013
-
Watch out for the Gorilla when Hiring Talent
July 19, 2013
-
Great Leaders Are Happy to Eat Humble Pie and Give the Credit to Others
June 21, 2013
-
Lessons Learned from the Firing Line of Interviewing in a Bi-lingual and Bi-cultural Environment
May 23, 2013
-
An Insider’s Perspective on Hiring in Japan
April 26, 2013
-
Pharmaceutical Companies in Japan Cross Cultural Boundaries to Retain and Hire the Best and the Brightest
March 18, 2013
-
Ichi-go Ichi-e - “One Opportunity, One Encounter”
February 20, 2013
-
Our Habits Are the Nuts and Bolts of Our Destiny
January 22, 2013
-
What Are Japanese Pharmaceutical Candidates Thinking?
December 18, 2012
-
Mid-Level Managers Seek More Guidance and Global Opportunities from Their Senior Management at Japan’s Multinational Pharmaceutical Companies
November 19, 2012
-
Leading from Afar
October 22, 2012
-
“Make Up Your Own Mind? What It Takes to Win Over Top-Tier Japanese Employees”
September 18, 2012
-
Our Habits Determine Our Success
August 8, 2012
-
Marketing Is More than a Pen and a Tissue Box
July 9, 2012
ページ
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…